Skip to Main Content

Author Details

Travis J Hollmann
Memorial Sloan Kettering Cancer Center
1998
88
38
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37029126Cross-platform dataset of multiplex fluorescent cellular object image annotations.Sci Data2023
37667855Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.J Pathol2023
37553760GABA Regulates Electrical Activity and Tumor Initiation in Melanoma.Cancer Discov2023
37494469Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse.Sci Transl Med2023
37009699Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology.Cancer Discov2023
37468587A spatially resolved timeline of the human maternal-fetal interface.Nature2023
37435097Stem cell-like T cell depletion in the recurrent head and neck cancer immune microenvironment.Oncoimmunology2023
37001503T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.Cell2023
34795433Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning.Nat Biotechnol2022
35545291Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.Int J Gynecol Cancer2022
35440124Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts.Nat Commun2022
35610143Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.Clin Breast Cancer2022
35532206Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma.Leuk Lymphoma2022
35662283Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.Nat Med2022
35445765Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus.J Cutan Pathol2022
36517593Ovarian cancer mutational processes drive site-specific immune evasion.Nature2022
36118303Deep Learning-Inferred Multiplex ImmunoFluorescence for Immunohistochemical Image Quantification.Nat Mach Intell2022
35074903Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.J Immunother Cancer2022
35013003Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma.Cancer Immunol Res2022
35146104Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer.Gynecol Oncol Rep2022
34815254Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy.Cancer Res2022
33372007Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.Cancer Discov2021
33625734Primary cutaneous SMARCB1-deficient carcinoma.J Cutan Pathol2021
33625139Treatment of Extramammary Paget Disease and the Role of Reflectance Confocal Microscopy: A Prospective Study.Dermatol Surg2021
33569903Monitoring vulvar melanoma response to combined immunotherapy and radiotherapy with in vivo reflectance confocal microscopy.J Dtsch Dermatol Ges2021
33790764Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report.Case Rep Oncol2021
33504552Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.Clin Cancer Res2021
34433638LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.Sci Transl Med2021
34653364Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.Cancer Cell2021
34653242A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.Blood2021
31633488Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.Am J Surg Pathol2020
31848819Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.Ann Surg Oncol2020
33458721Multimarginal Wasserstein Barycenter for Stain Normalization and Augmentation.Med Image Comput Comput Assist Interv2020
33004542Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.J Immunother Cancer2020
32707077Emergence of a High-Plasticity Cell State during Lung Cancer Evolution.Cancer Cell2020
32503949Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.J Immunother Cancer2020
32414858The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.J Immunother Cancer2020
32483290Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.Nat Genet2020
31355940C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.Histopathology2020
31582374ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer.Cancer Discov2020
30642912Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy.Clin Cancer Res2019
31692889Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A.Oncotarget2019
31391345Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.JCI Insight2019
30778169Whole slide imaging equivalency and efficiency study: experience at a large academic center.Mod Pathol2019
30851054Gram-negative cutaneous infections with unique filamentous forms.J Cutan Pathol2019
30791119Massively parallel sequencing analysis of benign melanocytic naevi.Histopathology2019
28654463Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.Am J Dermatopathol2018
30045064PRAME Expression in Melanocytic Tumors.Am J Surg Pathol2018
29903879Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.Cancer Discov2018
30061297Cancer modeling by Transgene Electroporation in Adult Zebrafish (TEAZ).Dis Model Mech2018
  • 1 - 50 of 88

Recommended Authors

Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 7
Carlos E de Andrea
University of Navarra
Career Start Year 2010
Number of shared co-authors 1
Mitchell P Levesque
University Hospital Zurich
Career Start Year 2009
Number of shared co-authors 6
Olivia M Lucero
Oregon Health & Science University
Career Start Year 2009
Number of shared co-authors 0
Xinmin Li
University of California los angeles
Career Start Year 2008
Number of shared co-authors 0
Phil F Cheng
University Hospital of Zurich
Career Start Year 2007
Number of shared co-authors 4
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 5
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 8
Michael G Ozawa
Stanford University School of Medicine
Career Start Year 2004
Number of shared co-authors 0
Shadmehr Demehri
Massachusetts General Hospital and Harvard Medical School
Career Start Year 2004
Number of shared co-authors 0
Raghwa Sharma
Westmead Hospital
Career Start Year 2004
Number of shared co-authors 2
Harriet M Kluger
Yale School of Medicine
Career Start Year 2003
Number of shared co-authors 8
Danh Tran-Thanh
Centre Hospitalier de l'Universite de Montreal
Career Start Year 2002
Number of shared co-authors 0
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2002
Number of shared co-authors 3
Marcory C R F van Dijk
1Rijnstate Hospital
Career Start Year 2001
Number of shared co-authors 0
Timo Gaiser
Institut fur Pathologie, Universitatsmedizin Mannheim
Career Start Year 2000
Number of shared co-authors 1
Christopher J Howlett
Western University
Career Start Year 1999
Number of shared co-authors 9
Gyeongsin Park
Seoul St. Mary's Hospital, The Catholic University of Korea
Career Start Year 1999
Number of shared co-authors 0
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Lawrence J Jennings
Northwestern University Feinberg School of Medicine
Career Start Year 1998
Number of shared co-authors 2
Sarah M Dry
Jonsson Comprehensive Cancer Center, University of California los angeles
Career Start Year 1992
Number of shared co-authors 3
Marcus Bosenberg
Yale School of Medicine
Career Start Year 1992
Number of shared co-authors 13
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Career Start Year 1989
Number of shared co-authors 19
Reinhard Dummer
University Hospital Zurich
Career Start Year 1988
Number of shared co-authors 9
Javed Siddiqui
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 1988
Number of shared co-authors 11
Stephen M Hewitt
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 7
Louis Gaboury
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 0
Phuong Nguyen
Hoag Memorial Hospital Presbyterian
Career Start Year 1983
Number of shared co-authors 7
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 4
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 15

Collaborators

Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Nicholas D Socci
Co-authored papers 6
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 5
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Michael F Berger
Co-authored papers 4
Richard M White
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Robert A Soslow
Co-authored papers 4
Michael Angelo
Co-authored papers 4
John T Poirier
Laura and Isaac Perlmutter Cancer Center
Co-authored papers 4
Ronglai Shen
Co-authored papers 4
Andrea Schietinger
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Arshi Arora
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Walid K Chatila
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Elisa de Stanchina
Co-authored papers 3
Umesh Bhanot
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Pier Selenica
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Andrew Chow
Co-authored papers 3
Cristina R Antonescu
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Dana Pe'er
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Lorenz Studer
The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 2
David Van Valen
California Institute of Technology, USA. institute of technology.edu.
Co-authored papers 2
Hira Rizvi
Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Richard Koche
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Felipe C Geyer
Instituto Do Cancer Do Estado de Sao Paulo
Co-authored papers 2
William Lee
Co-authored papers 2
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Co-authored papers 2
Release 1.2